VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 75 filers reported holding VAXCYTE INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,096,453 | +5.1% | 1,943,830 | +3.0% | 0.04% | +10.5% |
| Q2 2023 | $94,292,014 | +2917.0% | 1,888,106 | +2164.2% | 0.04% | +3700.0% |
| Q1 2023 | $3,125,382 | -11.5% | 83,388 | +13.2% | 0.00% | -50.0% |
| Q4 2022 | $3,533,340 | +225.7% | 73,688 | +63.0% | 0.00% | +100.0% |
| Q3 2022 | $1,085,000 | +10.3% | 45,200 | 0.0% | 0.00% | – |
| Q2 2022 | $984,000 | -7.4% | 45,200 | +2.7% | 0.00% | – |
| Q1 2022 | $1,063,000 | +20.4% | 44,000 | +18.6% | 0.00% | – |
| Q4 2021 | $883,000 | -6.2% | 37,100 | 0.0% | 0.00% | – |
| Q3 2021 | $941,000 | +38.4% | 37,100 | +22.8% | 0.00% | – |
| Q2 2021 | $680,000 | +53.8% | 30,200 | +34.8% | 0.00% | – |
| Q1 2021 | $442,000 | -36.9% | 22,400 | -15.2% | 0.00% | – |
| Q4 2020 | $701,000 | -46.2% | 26,400 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $1,304,000 | – | 26,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,457,300 | $54,619,604 | 23.40% |
| Pivotal bioVenture Partners Investment Advisor LLC | 693,039 | $25,975,102 | 10.70% |
| RA Capital Management | 7,291,254 | $273,276,200 | 6.19% |
| Kynam Capital Management, LP | 1,216,784 | $45,605,064 | 5.89% |
| GREAT POINT PARTNERS LLC | 659,211 | $24,707,228 | 4.85% |
| Frazier Life Sciences Management, L.P. | 1,397,405 | $52,374,739 | 3.79% |
| ACUTA CAPITAL PARTNERS, LLC | 120,500 | $4,516,340 | 3.33% |
| Ghost Tree Capital, LLC | 225,000 | $8,433,000 | 2.49% |
| Carlyle Group Inc. | 1,923,158 | $72,079,962 | 2.15% |
| Opaleye Management Inc. | 177,000 | $6,633,960 | 1.99% |